Intra-Cellular Therapies, Inc. (ITCI) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à New York City, NY, United States. Le PDG actuel est Sharon Mates.
ITCI a date d'introduction en bourse 2014-01-07, 860 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $14.05B.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company headquartered in New York that develops novel medications for neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms in the central nervous system. The company's approved product CAPLYTA treats schizophrenia in adults, while its clinical pipeline includes lumateperone in Phase III trials for bipolar depression and autism spectrum disorder, Lenrispodun for Parkinson's disease and heart failure, ITI-1284-ODT-SL for dementia-related behavioral disturbances, and ITI-333 for substance use disorders and psychiatric conditions. Founded in 2002, the company focuses on addressing significant unmet medical needs in the neuropsychiatric market through innovative drug development.
